Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse
neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract …

Gastrointestinal neuroendocrine tumors are rare slow-growing tumors with distinct
histological, biological, and clinical characteristics that have increased in incidence and …

Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of
somatotropinomas, thyrotropinomas, and functioning and non-functioning …

Summary Background Neuroendocrine tumours (NETs) can secrete bioactive amines into
the bloodstream, causing carcinoid syndrome, with symptoms including flushing and …

Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the
past decades, and are now the most common type of small bowel tumor. Consequently …

There have been significant developments in diagnostic and therapeutic options for patients
with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which …

Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase
inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

These guidelines update previous guidance published in 2005. They have been revised by
a group who are members of the UK and Ireland Neuroendocrine Tumour Society with …

Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are
also collectively known as midgut carcinoids. Similar to NETs in general, the diagnosed …